|Bid||351.74 x 1100|
|Ask||352.40 x 1000|
|Day's Range||344.85 - 354.32|
|52 Week Range||155.17 - 354.32|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||56.16|
|Forward Dividend & Yield||1.28 (0.37%)|
|Ex-Dividend Date||Nov 13, 2020|
|1y Target Est||N/A|
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at 8:00 a.m. CST to review second quarter 2021 financial results.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:00 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.